Paroxysmal Nocturnal Hemoglobinuria (PNH) Cell Models for Research

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematopoietic stem cell disorder characterized by chronic hemolysis, thrombosis, and bone marrow failure. The estimated prevalence is 1-5 per million individuals, with an incidence of about 1-2 new cases per million per year (WHO, 2023). The disease typically presents in the third to fourth decade of life, with a slight female predominance. Without treatment, the median survival is approximately 10-15 years, with thrombosis being the leading cause of death (NCI, 2023). The introduction of complement inhibitors (e.g., eculizumab) has significantly improved outcomes, but residual hemolysis and breakthrough disease remain challenges.

PNH is an ideal model for studying complement-mediated hemolysis, GPI-anchor biosynthesis, and clonal selection. The disease arises from somatic mutations in the PIGA gene, leading to deficiency of glycosylphosphatidylinositol (GPI)-anchored proteins, including complement regulators CD55 and CD59. This well-defined genetic basis allows for precise modeling using CRISPR technology. Public datasets, such as those from the International PNH Registry and various genomic studies, provide rich clinical and molecular data, enabling researchers to investigate genotype-phenotype correlations and clonal dynamics. Open questions include the mechanisms of clonal expansion, the role of additional mutations, and the development of resistance to complement inhibitors.

PNH is not a malignancy but a clonal hematopoietic disorder. The primary pathogenic pathway involves:

1. Somatic mutation in PIGA gene on X chromosome.

2. Loss of PIGA function leads to defective GPI anchor biosynthesis.

3. Deficiency of GPI-anchored proteins, notably CD55 and CD59, on red blood cells.

4. Uncontrolled complement activation on red blood cells, leading to intravascular hemolysis.

5. Chronic hemolysis releases free hemoglobin, causing nitric oxide depletion, smooth muscle dystonia, and thrombosis.

Additionally, bone marrow failure syndromes (e.g., aplastic anemia) may coexist, suggesting an autoimmune component that selects for PIGA-mutant clones.

Data from COSMIC and TCGA (though PNH is not in TCGA, COSMIC includes PIGA mutations).

PNH primarily involves complement pathway dysregulation. Key nodes include:

• • Complement C3 and C5 convertases: CD55 inhibits C3 convertase, CD59 inhibits membrane attack complex (MAC) formation.
• • Nitric oxide (NO) signaling: Free hemoglobin scavenges NO, leading to vasoconstriction and smooth muscle dysfunction.
• • Coagulation cascade: Hemolysis releases procoagulant factors, promoting thrombosis.
• • Inflammatory cytokines: Chronic hemolysis induces pro-inflammatory state, affecting endothelial function.

These networks are potential therapeutic targets.

Organoids derived from hematopoietic stem cells (HSPCs) can be used to model PNH, but are less common due to technical challenges. Gene-edited cell lines are preferred for high-throughput screening.

• • PDX models: Patient-derived xenografts in immunodeficient mice can recapitulate PNH hematopoiesis, but are limited by the rarity of the disease.
• • GEMM (Genetically Engineered Mouse Models): Conditional knockout of Piga in hematopoietic stem cells using Cre-lox systems has been generated, but mice do not fully recapitulate the hemolytic phenotype due to species differences in complement regulation.
• • Induced models: Treatment of mice with phenylhydrazine can induce hemolysis, but not specific to PNH.

These models are useful for studying clonal dynamics and testing therapies, but gene-edited cell lines offer more controlled in vitro systems.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific PIGA mutations. For example:

• • PIGA knockout cell lines: Complete loss of PIGA function, mimicking the most common PNH phenotype. These are generated by introducing frameshift mutations via CRISPR/Cas9.
• • PIGA point mutation knock-in lines: Specific mutations (e.g., c.1234C>T) can be introduced to study genotype-phenotype correlations.
• • Reporter lines: GFP or luciferase reporters under GPI-anchor promoters can be used to monitor GPI expression.

These models are commercially available from various sources, are sequence-verified, and are free of viral integration, making them ideal for drug discovery and functional studies.

Gene-edited PNH cell lines are used to validate the role of PIGA and other genes in GPI-anchor biosynthesis and complement susceptibility. For example, PIGA knockout lines can be complemented with wild-type or mutant PIGA to assess functional rescue. Additionally, CRISPR screens can identify modifiers of complement-mediated lysis, revealing novel therapeutic targets.

Isogenic pairs (PIGA wild-type vs. knockout) are used to screen complement inhibitors, such as eculizumab and ravulizumab. These models allow for high-throughput screening of new compounds that block complement activation. Resistance mechanisms can be studied by exposing cells to increasing concentrations of inhibitors and selecting for resistant clones, which can then be analyzed for secondary mutations.

CRISPR synthetic lethality screens can identify genes that are essential only in PIGA-deficient cells, providing potential biomarkers or therapeutic targets. For example, genes involved in complement regulation or oxidative stress response may be selectively required in PNH cells. Such screens can be performed using pooled sgRNA libraries in PIGA knockout vs. wild-type cells.